Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast... Curr Breast Cancer Rep (2017) 9:173–182 DOI 10.1007/s12609-017-0249-4 CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer 1 2 3 4 Somaira Nowsheen & Paul V Viscuse & Ciara C. O’Sullivan & Nicole P. Sandhu & 3 5 6 7 8 Tufia C. Haddad & Anne Blaes & Jennifer Klemp & Lara Nhola & Joerg Herrmann & Kathryn J. Ruddy Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 Abstract function in most cases. Severe trastuzumab-induced Purpose of Review Treatment with trastuzumab is a cornerstone cardiotoxicity is rare enough that the risk-benefit ratio still of human epidermal growth factor receptor 2 (HER2)-overex- weighs in favor of its use in the vast majority of patients with pressing breast cancer treatment, but carries an unfortunate risk HER2+ breast cancer. of toxicity to the cardiovascular system. Here, we review recent Summary An improved understanding of the pathophysiolo- findings on trastuzumab-associated cardiotoxicity, focusing on gy underlying trastuzumab-induced cardiotoxicity and the its incidence, diagnosis, and treatment. identification of patients at highest risk will allow us to con- Recent Findings Screening with multigated acquisition scan tinue to safely administer trastuzumab in patients with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

Loading next page...
 
/lp/springer_journal/incidence-diagnosis-and-treatment-of-cardiac-toxicity-from-trastuzumab-zvxhnOxCUD
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
D.O.I.
10.1007/s12609-017-0249-4
Publisher site
See Article on Publisher Site

Abstract

Curr Breast Cancer Rep (2017) 9:173–182 DOI 10.1007/s12609-017-0249-4 CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer 1 2 3 4 Somaira Nowsheen & Paul V Viscuse & Ciara C. O’Sullivan & Nicole P. Sandhu & 3 5 6 7 8 Tufia C. Haddad & Anne Blaes & Jennifer Klemp & Lara Nhola & Joerg Herrmann & Kathryn J. Ruddy Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 Abstract function in most cases. Severe trastuzumab-induced Purpose of Review Treatment with trastuzumab is a cornerstone cardiotoxicity is rare enough that the risk-benefit ratio still of human epidermal growth factor receptor 2 (HER2)-overex- weighs in favor of its use in the vast majority of patients with pressing breast cancer treatment, but carries an unfortunate risk HER2+ breast cancer. of toxicity to the cardiovascular system. Here, we review recent Summary An improved understanding of the pathophysiolo- findings on trastuzumab-associated cardiotoxicity, focusing on gy underlying trastuzumab-induced cardiotoxicity and the its incidence, diagnosis, and treatment. identification of patients at highest risk will allow us to con- Recent Findings Screening with multigated acquisition scan tinue to safely administer trastuzumab in patients with

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Jul 14, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off